The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Highlights for MRD assessment in AML

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Lars Bullinger, Charité – Universitätsmedizin Berlin, Berlin, DE, about the highlights for measurable residual disease (MRD) assessment in AML from ASH 2020.

ASH 2020: Highlights for MRD assessment in AML

Bullinger mentions three studies presented at ASH 2020: the first one investigating the effectiveness of MRD eradication with chemotherapy prior to allogeneic stem cell transplantation in AML; the second study evaluating NPM1 as a molecular marker for MRD; and the last one focusing on new technologies for MRD assessment.

Bullinger kindly gave his interview in German, with the title 'ASH 2020: Highlights zum MRD Monitoring bei der AML'.